Citi Reiterates Sell Rating on Hims and Hers (HIMS), Comments on Novo's Wegovy Price Promo: 'We see this as another potential headwind for HIMS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Citi Drops Third Note on Hims and Hers (HIMS) Inside 20 Hours: 'HIMS is now offering discounts on its bundles, effectively passing through the price discount'
May 22, 2025 2:50 PM EDT(Updated - May 22, 2025 2:52 PM EDT)
Citi analyst Daniel Grosslight reiterated a Sell rating and $30.00 price target on Hims and Hers (NYSE: HIMS)
The analyst comments "In response to Novo lowering the cash pay price of Wegovy to $199 for the first month... More
Hims & Hers Health: Analysts remain bearish
May 22, 2025 9:49 AM EDTInvesting.com -- Analysts at Citi and Bank of America are maintaining a cautious stance on Hims & Hers Health (NYSE: HIMS) as competition in the GLP-1 space intensifies and growth begins to moderate.
In a note Thursday, Citi flagged potential pressure from Evernorths newly announced benefit that caps patient out-of-pocket costs for GLP-1... More
Morgan Stanley Reiterates Equalweight Rating on Hims and Hers (HIMS)
May 22, 2025 5:34 AM EDTMorgan Stanley analyst Craig Hettenbach reiterated an Equalweight rating and $40.00 price target on Hims and Hers (NYSE: HIMS).
The analyst comments "Him & Hers app downloads increased 25% y/y... Third party data suggests 25% y/y growth in app downloads in the month of April ( Exhibit 2 ). App downloads... More
Truist Securities Reiterates Hold Rating on Hims and Hers (HIMS)
May 22, 2025 5:33 AM EDTTruist Securities analyst Jailendra Singh reiterated a Hold rating and $45.00 price target on Hims and Hers (NYSE: HIMS).
The analyst comments "Thoughts on Evernorth's Weight Loss Drugs Coverage Announcement. On 5/21, after the close, Evernorth (part of Cigna, CI, Buy, MacDonald) announced a pharmacy benefit offering that would make weight loss medications Wegovy and Zepbound available at a monthly cost not exceeding $200 to patients, with the added benefit of counting towards the patient's annual... More
BofA Securities Negative on Hims and Hers (HIMS): 'Observed total sales and GLP-1 sales decline in April'
May 22, 2025 5:16 AM EDTBofA Securities analyst Michael Cherny reiterated an Underperform rating and $28.00 price target on Hims and Hers (NYSE: HIMS)
The analyst comments "Observed sales data continues to weaken sequentially. Observed sales growth y/y decelerated 6ppts from March with sales down 6% m/m (3% adj. for days) and GLP-1 sales declined for the 2nd consecutive month. While... More
Citi Reiterates Sell Rating on Hims and Hers (HIMS), PT $30, 'we do think that this will be a slight headwind to HIMS'
May 22, 2025 4:56 AM EDTCiti analyst Daniel Grosslight reiterated a Sell rating and $30.00 price target on Hims and Hers (NYSE: HIMS)
The analyst comments "This afternoon, Evernorth announced it is launching a new benefit option that caps patient OOP costs for Wegovy and Zepbound at... More
